Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05945823 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
A Phase 2 study of Pancreatic Cancer and Esophageal Adenocarcinoma, sponsored by Taiho Oncology.
- Active
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
- 20
- Study locations
NCT05945823 is a Phase 2 study of Pancreatic Cancer and Esophageal Adenocarcinoma that is active but no longer recruiting, run by Taiho Oncology. The registered enrollment target is 53 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT05945823, a Phase 2 study of Pancreatic Cancer and Esophageal Adenocarcinoma, is active but no longer recruiting, sponsored by Taiho Oncology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a nonrandomized, uncontrolled, open-label, multicenter Phase 2 study to evaluate the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-based SoC therapy in adult patients with solid tumors.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Cisplatin
- DRUG Oxaliplatin
- DRUG 5-FU
- DRUG Futibatinib
Study Locations (20)
Other
- Centre Hospitalier Regional Universitaire de Lille - Lille
- Centre Hospitalier Regional Universitaire Poitiers - Poitiers
- Krankenhaus Nordwest gGmbH - Frankfurt
- Universitaetsmedizin Mainz - Mainz
Florida
- Mount Sinai Comprehensive Cancer Center - Miami Beach
- Moffitt Cancer Center and Research Institute - Tampa
New York
- Roswell Park Comprehensive Cancer Center (RPCCC) (Roswell Park Cancer Institute (RPCI)) - Buffalo
- NYU Langone - New York
Virginia
- Inova Schar Cancer Institute - Fairfax
- Blue Ridge Cancer Care - Roanoke
California
- University of California Los Angeles UCLA - Cancer Care - Santa Monica - Santa Monica
Colorado
- Rocky Mountain Cancer Centers Midtown - Denver
Michigan
- Henry Ford Health System - Detroit
New Jersey
- The Minniti Center - Medical Oncology and Hematology - Mickleton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2023-07-13 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05945823
The ClinicalTrials.gov registry entry for NCT05945823 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (87% lower). The listed sponsor is Taiho Oncology, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT05945823 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT05945823 about?
NCT05945823 is a clinical study titled "Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors". This is a nonrandomized, uncontrolled, open-label, multicenter Phase 2 study to evaluate the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-based SoC therapy in adult patients with solid tumors.
What is the current status of trial NCT05945823?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2023-07-13. Estimated completion is 2027-01.
What conditions does trial NCT05945823 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Siewert Type 1 GEJ Cancer.
What interventions are being tested in trial NCT05945823?
The interventions under investigation include: Pembrolizumab (DRUG), Cisplatin (DRUG), Oxaliplatin (DRUG), 5-FU (DRUG), Futibatinib (DRUG).
Who is sponsoring clinical trial NCT05945823?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05945823 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Michigan, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.